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ABSTRACT
Parkinson’s disease (PD) and Alzheimer’s Disease (AD) are severe neurodegene-
rative disorders, with no drugs that are currently approved to prevent the neuronal cell 
loss characteristic in brains of patients suffering from PD and AD and all drug 
treatment are synptomactic. Due to the complex pathophysiology, including a cascade 
of neurotoxic molecular events that results in neuronal death and predisposition to 
depression and eventual dementia and etiology of these disorders, an innovative 
approach towards neuroprotection or neurorestoration (neurorescue) may be the de-
velopment and use of multifunctional pharmaceuticals. Such drugs target an array of 
pathological pathways, each of which is believed to contribute to the cascades that 
ultimately lead to neuronal cell death. In this short review, we discuss examples of 
novel multifunctional ligands that may have potential as neuroprotective-neurorestora-
tive therapeutics in PD and AD. The compounds discussed originate from synthetic 
chemistry as well as from natural sources. 
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INTRODUCTION
    Parkinson’s  disease  (PD)  is  an  age-related  neu-
rodegenerative  disease  with  progressive  loss  of 
dopaminergic  (DA)  neurons  in  the  substantia  nigra 
pars compacta (SNpc). In patients, this depletion of 
neurons presents clinically with severe motor symp-
toms  including  uncontrollable  resting  tremor,  bradi-
kinesia,  rigidity  and  postural  imbalance  (Lang  and 
Lozano,  1998a;  1998b;  Lotharius  and  Brundin, 
2002).  These  symptoms,  which  affect  1%  of  in-
dividuals over the age of 65, start to manifest when 
70∼80%  of  DA  neurons  in  the  SNpc  are  lost 
(Mandel  et  al.,  2003;  Meissner  et  al.,  2004).  The 
exact etiology of PD remains to be fully elucidated, 
but the key theories propose either an environmen-
tal  (e.g.  insecticides  (Calne  et  al.,  1987;  Schoen-
berg,  1987;  Paolini  et  al.,  2004))  or  a  genetic  (e.g. 
parkin (Kitada et al., 1998)) origin, or a combination 
of  both. 
    In  2009,  the  market  value  for  PD  and  AD  the-
rapies  exceeded  US$6.5  billion,  (Schapira  et  al., 2 Moussa  B.  H.  Youdim
Table  1.  Definitions  of  the  terms  neuroprotection,  neuro-
restoration  and  neurorescue
Neuroprotection A  beneficial  interaction  that  prevents  or 
slows  neurons  from  dying  (Mandel  et  al., 
2003). A need for disease presymptomatic 
biomarker.
Neurorestoration A  beneficial  interaction  that  replaces  dying 
or  dead  neuronal  cells  with  viable  cells 
(Mandel et al., 2003). Acting during symp-
tomatic  phase.
Neurorescue A  beneficial  interaction  that  rescues  cells 
where  neuronal  cell  death  has  already 
started (Foley, 2000). Acting during symp-
tomatic  phase 
Fig. 1. Three approaches towards combination drug therapy in a 
multi-target  disease  (adapted  from  (MorphyRankovic,  2005)).
2005)  with  projections  that  these  will  surpass  can-
cer as the second most common cause of death of 
the  elderly  (Lang  and  Lozano,  1998a).  Therefore, 
there  is  a  real  sense  of  urgency  to  discover  novel 
therapies for the treatment or preferably, prevention 
of  these  diseases.  Currently  the  only  therapies 
approved  for  the  treatment  of  PD  and  AD  are 
agents  that  attenuate  the  symptoms  (symptomatic) 
of  the  disease  without  disease  modifying  activity 
except  the  anti  Parkinson  drug  rasagiline  (Azilect) 
(Olanow et al., 2009), which we developed (Youdim 
et  al.,  2005).  The  mainstay  for  PD  treatment 
focuses on the replacement of lost DA with L-dopa, 
dopamine  (DA)  agonists,  monoamine  oxidase  B 
inhibitors  and  catechol-O-methyl  tranferase  inhibi-
tors, thereby normalizing the patient symptomatically 
(Schapira  et  al.,  2005).  While  for  AD  there  are  the 
cholinesterase  inhibitors  and  the  glutamate  anta-
gonist  memantine.  Tragically,  but  important  in  view 
of  the  seriousness  of  disease  progression,  is  the 
fact  that  the  course  of  the  disease  is  not  affected 
by  the  utilization  of  these  drugs,  and  the  loss  of 
neurons  continues  unabated  even  as  symptoms 
may  be  controlled,  at  least  following  initial  treat-
ment.  Currently,  no  drugs  with  claimed  neuropro-
tective activity have been approved by the FDA for 
the treatment of PD or AD (Table 1) (Mandel et al., 
2003;  Stocchi  and  Olanow,  2003).  Significantly 
though,  recent  research  has  suggested  that  some 
drugs  used  for  symptomatic  relief  in  PD,  such  as 
Azilect,  pramipexole  (Hall  et  al.,  1996;  Dooley  and 
Markham,  1998;  Piercey,  1998)  and  memantine 
(Rogawski  and  Wenk,  2003;  Plosker  and  Lyseng- 
Williamson, 2005) may also possess neuroprotective 
activities,  rasagiline  is  currently  only  drug  that  may 
have  a  disease  modifying  activity  (Olanow  et  al., 
2009).
    Recent  literature  show  that  there  has  been  a 
paradigm  shift  in  the  way  researchers  are  con-
sidering  the  development  and  design  of  drugs  to 
treat  diseases  with  complex  etiological  pathways 
(i.e. diseases with multiple drug targets) (Morphy et 
al.,  2004;  Gal  et  al.,  2005;  Morphy  and  Rankovic, 
2005;  Youdim  and  Buccafusco,  2005a;  2005b;  Van 
der Schyf et al., 2006a; 2006b; Zimmermann et al., 
2007).  In  a  pathway  system  with  a  multitude  of 
drug targets, a drug with a single-target mechanism 
of  action  cannot  always  compensate  or  correct  a 
complex  pathway,  which  suggests  that  a  complex 
pathway  disease  should  be  treated  1)  with  a  mul-
titude  of  molecules,  each  acting  on  different  path-
ways in the disease (polypharmacy), or 2) with one 
molecule that possesses promiscuous activity acting 
on  different  pathways  (multiple  mechanism  drugs). 
    Polypharmacy  (Fig.  1)  therefore,  is  the  clinical 
practice of combining two or more medications in a 
patient’s medication profile, with a view to treat one 
specific  disease.  For  example,  the  combination  use Neuroprotective  and  Neurorestorative  Drugs 3
Fig.  2.  Chemical  structures  of  Selegiline  and  Rasagiline.
of  salmeterol  (a  β2-adrenergic  agonist)  and  flu-
ticasone  (a  glucocorticoid  steroid)  in  asthma,  has 
led  to  the  combination  of  these  two  medications  in 
one  (Advair
Ⓡ).  Also,  the  combination  (in  Vytorin
Ⓡ) 
of  simvastatin  (an  HMG-CoA  reductase  inhibitor) 
and  ezetimibe  (an  inhibitor  of  dietary  cholesterol 
uptake)  is  used  to  treat  hyperlipidemia  (Zimmer-
mann et al., 2007). The major dilemma encountered 
in  a  polypharmaceutical  approach,  is  a  significant 
chance  increase  in  side  effects,  which  may  be 
reduced  statistically  with  the  use  of  only  one 
compound.  The  recent  appearance  on  the  market 
of  drugs  that  display  two  mechanisms  to  treat  a 
particular  disease  has  been  a  clear  move  in  the 
direction  of  the  latter  paradigm.  One  example, 
duloxetine  (Cymbalta
Ⓡ),  used  in  the  treatment  of 
depression,  inhibits  both  serotonin  and  norepine-
pherine uptake in the central nervous system (CNS) 
(Wong et al., 1988; KiharaIkeda, 1995; Goldstein et 
al.,  2002).  The  introduction  of  drugs  such  as  du-
loxetine  indicates  the  clinical  feasibility  of  designing 
multi-functional  ligands  to  treat  CNS  disorders  with 
complex  disease  pathways. 
    In  this  review,  we  will  consider  examples  of 
compounds  with  multi-functional  neuroprotective- 
neurorescue  (Table 1  for  definitions)  properties that 
may  have  promise  in  the  treatment  of  PD  and 
similar  approaches  have  been  made  for  multimodal 
drugs  for  AD  (Youdim  et  al.,  2006;  Zheng  et  al., 
2009), but for the present discussion we shall focus 
on  PD  only.  Some  of  the  compounds  discussed 
were  discovered  through  serendipity  while  others 
were  the  products  of  active  drug  design  projects. 
Rasagiline
    Rasagiline is a newly approved compound for the 
treatment  of  PD  (Fig.  2;  Schapira  et  al.,  2005). 
Rasagiline  (N-propargyl-1R-aminoindan)  is  an  anti- 
PD  drug  with  selective  MAO-B  inhibitory  activity 
(Youdim  et  al.,  2005a).  Its  S  isomer,  TV1022 
(N-propargyl-1S-aminoindan),  is  more  than  a  1,000 
times  less  potent  as  an  MAO  inhibitor  than  ra-
sagiline,  but  still  retains  neuroprotective  activity, 
which  suggests  that  the  propargylamine  moiety 
(even  when  ostensibly  not  involved  in  Michael 
chemistry  at  the  FAD  within  the  MAO  catalytic  site 
as  the  processing  group  in  suicide  inhibition)  is 
responsible  for  the  neuroprotective  activity  seen  in 
both  these  compounds  (Weinreb  et  al.,  2004a; 
Bar-Am  et  al.,  2005;  Youdim  et  al.,  2005b;  Zheng 
et  al.,  2005a). 
    The  selectivity  of  rasagiline  as  an  MAO-B  in-
hibitor  compared  with  TVP-1022,  is  thought  to  be 
associated with  the ability of  rasagiline  to enter the 
catalytic  site  gorge  of  MAO-B.  On  the  other  hand, 
the  configuration  of  the  S-isomer  imparts  a  highly 
restrictive  conformation  on  the  enzyme-ligand  com-
plex, which prevents the molecule from entering the 
catalytic  site,  precluding  it  from  acting  as  a  me-
chanism-based  inhibitor.  Interestingly,  the  neuro-
protective activity associated with these compounds 
has  now  been  shown  to  be  associated  with  the 
ability  of  propargylamine  (Weinreb  et  al.,  2004a; 
Bar-Am  et  al.,  2005)  to  protect  mitochondrial 
viability  by  activation  of  Bcl-2  and  protein  kinase  C 
(PKC)α  and  ε,  and  by  down  regulating  pro- 
apoptotic  FAS  and  Bax,  and  PKCδ  and  -γ 
(Youdim  et  al.,  2005a).  Additionally,  these  drugs 
induce  the  release  of  the  soluble  neuroprotective- 
neurotrophic  form  of  the  amyloid  precursor  protein 
α  (sAPPα)  through  a  PCK-MAP  mediated  ac-
tivation  of  α-secretase  (Youdim  and  Buccafusco, 
2005b). 
    The identification of the propargylamine moiety as 
a  key  element  that  confers  neuroprotective  activity 
and,  in  cases  such  as  rasagiline  and  selegiline, 
also MAO inhibitory activity, led to the development 
of  AchE  inhibitors  such  as  ladostigil  (TV3326,  now 4 Moussa  B.  H.  Youdim
Fig.  3.  Design  of  Ladostigil.
Fig.  4.  Chemical  structures  of  M30  and  HLA20.
in  phase  II  clinical  studies),  another  anti-Alzheimer 
(AD)/anti-PD/antidepressant  drug  (Sterling  et  al., 
2002; Weinstock et al., 2002; Youdim et al., 2005a; 
Youdim  and  Buccafusco,  2005b).  Ladostigil  (Fig.  3) 
is  a  dual  acetylcholine-butyrylcholine-esterase,  and 
brain-selective  MAO-A/B  inhibitor  in  vivo,  designed 
by  combining  the  carbamate  cholinesterase  inhibi-
tory moiety found in the rivastigmine molecule, with 
the pharmacophore of rasagiline and TVP1022 both 
of  which  possess  the  propargylamine  moiety.  La-
dostigil  has  been  shown  to  have  antidepressant 
activity  due  to  its  ability  to  inhibit  MAO-A  in  the 
raphe  nucleus,  striatum,  hippocampus,  and  hypo-
thalamus,  and  to  raise  brain  levels  of  DA,  no-
repinephrine, and serotonin (Weinstock et al., 2002). 
Its  ability  to  also  inhibit  MAO-B  attenuates  1- 
methyl-4-phenyl-1,2,3,6-tetrahydropyridine  (MPTP) 
toxicity  in  mice,  a  rodent  model  of  parkinsonism 
(Sagi  et  al.,  2003).  Although  a  poor  MAO-B  in-
hibitor,  the  S  isomer  of  ladostigil,  TV3279,  has 
shown  similar  neuroprotective  activity  to  rasagiline 
and  ladostigil  in  vitro  and  in  laboratory  animals 
(Youdim  and  Buccafusco,  2005b),  with  molecular 
mechanisms  apparently  identical  to  that  of  rasa-
giline.
Iron  chelators  with  radical  scavenging  and 
brain-selective  monoamine  oxidase  inhibitory 
activity
    Degenerating  nigrostriatal  DA  neurons  are  the 
main  pathological  feature  in  the  SNpc  of  PD 
sufferers.  In  addition,  many  PD  patients  also  ex-
perience  dementia  and  depression  that  likely  result 
from  sporadic  neurodegeneration  in  cholinergic, 
noradrenergic,  and  serotonergic  pathways.  In  PD, 
accumulation  of  iron  is  found  inside  some  me-
lanin-containing  DA-ergic  neurons  and  inside  am-
yloid  plaques  and  neurofibrillary  tangles  associated 
with PD dementia (Zecca et al., 2004). It has been 
suggested  that  iron  accumulation  may  contribute  to 
the  oxidative  stress-induced  apoptosis  reported  in 
both  PD  and  PD  dementia  (Zecca  et  al.,  2004; 
Youdim  et  al.,  2005b).  Such  oxidative  stress  may 
result  from  increased  glial  monoamine  oxidase 
(MAO)  activity  leading  to  exacerbated  hydrogen 
peroxide  production  that  can  generate  reactive 
hydroxyl  radical  through  Fenton  chemistry  with 
intracellular  ferrous  iron.  Iron  chelators  such  as 
desferoxamine,  clioquinol  and  VK-28  have  been 
shown  to  have  neuroprotective  activity  in  animal 
models  of  AD  and  PD  (Zecca  et  al.,  2004). 
    Based  on  this  proposal,  Zheng  et  al.  (2005b) 
developed  neuroprotective  compounds  with  dual 
iron  chelating  and  MAO-B  inhibitory  activity.  These 
authors  combined  the  antioxidant  chelator  moiety 
present  in  an  8-hydroxyquinoline  derivative  of  the 
neuroprotective  brain-permeable  iron  chelator  VK- 
28,  with  the  propargylamine  moiety  (found  in  com-
pounds such as rasagiline and selegiline, as stated Neuroprotective  and  Neurorestorative  Drugs 5
Fig.  5.  Neuroprotective  effects  of  M30.  See  text  for  discussion.
Fig.  6.  Novel  multimodal  cholinesterase-iron  chelating-radical 
scavenging  drug  for  Alzheimer;  disease  (Zheng  et  al.,  2006).
earlier).  HLA20  was  identified  as  a  potential  lead 
compound  for  further  studies  having  selectivity  for 
MAO-B with  an IC50  value  in  the  region  of  110μM 
(Fig. 4; ＞200μM for MAO-A), as well as acting as 
a  free  radical  scavenger.  However,  a  related 
compound  designated  M30,  unlike  HLA20  was 
found  in  vitro,  to  be  a  highly  potent  MAO-A  and  B 
inhibitor  with  brain  selectivity  for  these  enzymes  in 
vivo,  in  addition  to  possessing  iron  chelating  pro-
perties  similar  to  desferoxamine  (Gal  et  al.,  2005; 
Zheng et al., 2005a; 2005b). M30 behaves similarly 
to other propargylamine MAO inhibitors by acting as 
a  suicide-  or  mechanism-based  inhibitor  after  being 
identified  and  processed  as  a  substrate  by  the 
enzyme  and  imparts  similar  neuroprotective  pro-
perties  as  those  found  in  rasagiline  and  ladostigil 
(Fig.  5).  M30  protects  against  MPTP  and  kainate 
neurotoxicity  in  mice  by  virtue  of  both  its  MAO 
inhibitory  and  iron  chelating/radical  scavenging  pro-
perties  in  these  two  animal  models  of  neurode-
generation.  It  has  recently  been  shown  to  have 
dopaminergic  neurorestorative  activity  in  post  treat-
ment  with  MPTP  (Gal  et  al.,  2009)  and  lactacystin 
(Zhu  et  al.,  2007)  models  of  PD.  The  neurogenic 
activity  of  M30  and  HLA-20  has  been  attributed  to 
the inhibition of iron dependent prolyl-4-hydroxylase, 
via  chelation  of  iron  and  activation  of  HIF  (hypoxia 
inducing  factor)  that  regulates  transcription  of  a 
series  of  neurotropins  such  as  BDNF,  GDNF, 
erythropoietin and VEGF. The Consequence of HIF 
activation  is  inhibition  of  cell  cycle  G
0/G
1,  that 
results  in  inhibition  of  cyclin  D1  that  causes  cell 
arrest  differentiation  into  neurons  as  seen  in  the 
neurorestorative  activity  of  M30  in  the  two  models 
of  PD  (Zhu  et  al.,  2007;  Gal  et  al.,  2009;  Ku-
pershmidt  et  al.,  2009). 
    For  AD  therapeutics  we  have  introduced  a  car-
bamate  cholinesterase  inhibitor  (ChEI)  moieties  into 
M30,  such  as  M30C-N  and  into  HLA-20  to  give 
HLA-20A  and  have  even  added  the  glutamate 
antagonist,  memantine,  which  is  presently  in  the 
clinical  use.  These  compounds  HLA-20A  (Fig.  6) 
and  M30C-N  (Fig.  7)  have  been  shown  to  have 
potent  ChE  I  and  MAO-A  and  B  inhibitory  activity 
and possess similar neuroprotective activity to those 
of  their  parent  compounds,  HLA-20  and  M30 
(Zheng  et  al.,  2009).
    The  accumulation  of  iron  at  sites  where  neurons 
degenerate  in  PD,  is  thought  to  be  a  major  event 
that  is  linked  to  the  neurodegenerative  process 
(Zecca  et  al.,  2004).  The  novel  non-toxic  lipophilic 
(and  therefore  brain-permeable)  iron  chelator  VK- 
28,  and  its  multi-functional  derivative,  M30  (both  of 
which  possess  the  MAO  inhibitory  and  neuro-
protective  propargyl  moiety  of  rasagiline),  offer 
potential  therapeutic  benefits  for  PD.  M30  at-
tenuates  apoptotic  events  in  SH-SY5Y  neurobla-
stoma  cells  in  a  serum  deprivation  model  via 
multiple  protection  mechanisms,  including  1)  re-
duction of the  pro-apoptotic proteins, Bad and  Bax; 
2)  reduction  of  apoptosis-associated  Ser139-pho-
sphorylated H2A.X; 3) induction of the anti-apoptotic 
protein,  Bcl-2  and  4)  inhibition  of  the  cleavage  and 
activation  of  caspase-3.  M30  also  promotes  mor-
phological  changes,  resulting  in  axonal  growth- 
associated protein-43 (GAP-43), which is implicated 
in  neuronal  differentiation.  The  compound  markedly 6 Moussa  B.  H.  Youdim
Fig.  7.  Novel  multimodal  choline-
sterase-monoamine  oxidase  inhibi-
tor-iron  chelator-radical  scavenger 
for  Alzheimer’s  disease  with  par-
kinsonism,  Parkinson’s  disease  with 
dementia  and  Lewy  body  disease 
(submitted  for  publication).
reduces  the  levels  of  cellular  holo-APP,  the  β- 
C-terminal  fragment  (β-CTF),  and  levels  of  amy-
loidogenic  Aβ peptide  in  the  medium  of  SH-SY5Y 
and  CHO  cells  stably  transfected  with  the  APP 
“Swedish”  mutation.  In  addition,  levels  of  the  non- 
amyloidogenic  sAPPα in  cell  medium,  as  well  as 
levels  of  α-CTF  in  cell  lysate  were  found  to  be 
elevated.  These  results  are  consistent  with  the 
presence of an iron-responsive element (IRE) in the 
5'-untranslated  region  (5'UTR)  of  APP  and  de-
monstrate  the  effectiveness  of  M30  in  limiting 
holo-APP  expression  and  Aβ  peptide  secretion. 
Therefore,  the  multifunctional  properties  of  M30 
suggest  that  it  may  offer  extraordinary  potential  as 
a  drug  for  the  treatment  of  PD,  especially  PD 
dementia  (Avramovich-Tirosh  et  al.,  2006)  and  AD 
(Mandel  et  al.,  2007;  Amit  et  al.,  2008)  and  more 
recently  in  transgenic  G93A  SOD  model  of  ALS 
(amyotrophic  lateral  sclerosis)  where  it  extends  the 
life  span  of  these  animals  and  has  neurogenic 
activity  in  NCS-34  rat  motor  neurons  (Kupershmidt 
et  al.,  2009).
Monoamine  oxidase  inhibition  by  A2Areceptor 
antagonists
    In  PD,  a  dual  mechanism  that  includes  inhibition 
of  MAO-B,  as  well  as  adenosine  A2A  receptor 
blockade  offer  a  novel  therapeutic  approach  to Neuroprotective  and  Neurorestorative  Drugs 7
Fig.  8.  Chemical  structures  of  adenine  receptor  antagonists.
prevent  neuronal  cell  death  (Fig.  9).  As  detailed 
earlier,  MAO-B  plays  a  role  in  the  catabolism  of 
neurotransmitters  such  as  DA,  serotonin  and  no-
repinephrine,  leading  to  hydrogen  peroxide  for-
mation  which  contributes  to  oxidative  stress  and 
neuronal  cell  death  (Riederer  et  al.,  2004).  Levels 
of  MAO-B  are  found  to  be  increased  in  older 
patients  (Saura  et  al.,  1994;  1997;  Mahy  et  al., 
2000)  which  has  led to  the  rationale  for  the  use  of 
drugs such as selegiline (deprenyl) and lazabemide, 
(Sramek and Cutler, 1999) and the design of drugs 
such as ladostigil, (Youdim and Buccafusco, 2005b) 
as  described  before.
    Caffeine,  a  non-selective  adenosine  receptor  an-
tagonist, is under some scrutiny as a potential drug 
to  counteract  age-related  cognitive  decline  (Fig.  8). 
Work  in  this  regard  is  supported  by  evidence  that 
critical  changes  in  adenosine-related  neurotrans-
mission  occur  with  aging  and  may  be  counteracted 
by  adenosine  receptor  antagonists  (Maiade  and 
Mendonca, 2002; Dall'Igna et al., 2003; Prediger et 
al., 2005). Caffeine, in fact, has been suggested to 
protect  against  β-amyloid  neurotoxicity,  (Dall'Igna 
et  al.,  2003)  while  acute  treatment  with caffeine 
and  the  A2A  receptor  antagonist  ZM241385  was 
recently  found  to  reverse  age-  related  olfactory 
deficits and memory decline in rats (Prediger et al., 
2005) clearly suggesting involvement of A2A, but not 
A1  receptors,  in  cognitive  decline  and  possibly, 
neurodegenerative processes. Evidence such as the 
preceding,  and  other  evidence  for  neuroprotection 
also  in  parkinsonian  models,  led  Petzer  et  al. 
(Petzer  et  al.,  2003)  to  evaluate  (E)-8-styryl- 
xanthinyl  derived  adenosine  A2A  receptor  anta-
gonists  for  inhibition  also  of  brain  MAO-B.  Included 
in  these  studies  were  KW-6002,  a  potent  A2A 
receptor  antagonist  (Ki  of  2.2  nM)  which  is  un-
dergoing  clinical  trials  for  PD,  and  (E)-8-(3-chlo-
rostyryl)-caffeine  (CSC;  Fig.  8),  which  has  been 
shown  to  be  neuroprotective  in  the  MPTP  par-
kinsonian  mouse  model  (Chen  et  al.,  2002).  All  of 
the  compounds  tested  in  the  studies  by  Petzer  et 
al. (Petzer et al., 2003) showed MAO-B inhibition in 
the  low  micromolar  to  high  nanomolar  range,  with 
the  Ki  of  KW-6002  at  21μM,  and  that  of  CSC  at 
0.1μM.  These  results  clearly  suggest  that  the 
neuroprotective  properties  of  KW-6002  and  CSC 
may  in  part  be  due  to  MAO-B  inhibition,  in  sy-
nergism  with  the A2A  antagonism (Castagnoli  et al., 
2003).
NMDA antagonism by calcium channel blockers
    The  divalent  calcium  cation  plays  an  important 
role  in  neuronal  cell  death  (Lipton,  1999;  Horn  and 
Limburg,  2000;  Kemp  and  McKernan,  2002;  Ov-
biagele et al., 2003). One of the receptors activated 
by  glutamate  (together  with  its  co-agonist  glycine), 
the NMDA receptor, is a major conduit for the influx 
of  calcium  ions  into  cells  under  excitotoxic  con-
ditions.  The  prevention  of  such  excessive  influx  of 
calcium  (known  as  excitotoxicity)  therefore  remains 
a major drug target in the design of neuroprotective 
agents. Excess accumulation of calcium in neuronal 
cells rapidly leads to cell death through a variety of 
mechanisms  including  activation  of  proteases,  nu-
cleases,  phospholipases,  nitric  oxide  synthase 
(NOS),  and  other  degradative  enzymes  that  not 
only  lead  to  activation  of  death  cascades,  but  also 8 Moussa  B.  H.  Youdim
Fig.  9.  Dual  mechanism  of  MAOB/ 
A2A  antagonists  in  a  neuron.
to  free  radical  formation  (Lipton,  1999).  NMDA 
receptor  antagonists  such  as  dizocilpine  (MK-801) 
and memantine may possess a dual mechanism by 
which  neuronal  cells  are  protected,  both  by  direct 
blockade  of  the  NMDA  receptor  and  by  attenuating 
TNFα-induced  potentiation  of  glutamate  toxicity 
(Zou  and  Crews,  2005).
    Brain  injury  after  ischemic  stroke  also  triggers  a 
release  of  glutamate-associated  excitotoxic  events, 
and  the  incidence  of  cognitive  impairment  and 
dementia  have  both  been  reported  to  be  elevated 
after  cerebral  stroke,  especially  in  the  elderly 
(KalariaBallard, 2001). Up to 25% of stroke patients 
exhibit  symptoms  of  dementia,  including  symptoms 
reminiscent  of  PD  dementia  (van  Kooten  and 
Koudstaal,  1998).  Stroke  is  the  third  leading  cause 
of  death  in  the  United  States  (Ovbiagele  et  al., 
2003)  and  there  is  a  definitive  need  to  develop 
drugs  that  can  protect  or  save  neurons  after  an 
ischemic  incident  since,  to  date,  no  effective  treat-
ment has been developed to prevent neuronal cells 
from  dying  during  stroke  conditions  (Horn  and 
Limburg,  2000).
    Several  studies  have  shown  that  NMDA  receptor 
antagonists,  such  as  dizocilpine  (MK-801)  and  the 
polycyclic  cage  amine  memantine,  display  neuro-
protective  effects  in  experiments  using  ischemia 
paradigms  in  neurons  (Gorgulu  et  al.,  2000;  Horn 
and  Limburg,  2000;  Gerriets  et  al.,  2003;  Richard 
Green  et  al.,  2003).  An  alternative  pathway  for 
calcium  to  enter  into  neuronal  cells  is  through 
voltage-gated  ion  channels,  such  as  L-type  calcium 
channels. Animal experiments with nimodipine have 
suggested that calcium channel antagonists may be 
neuroprotective  in  ischemia  by  antagonizing  the 
influx  of  calcium  into  neuronal  cells  (Horn  and 
Limburg, 2000). The importance of calcium overload 
during  cell  death,  suggests  that  a  dual  calcium 
channel  and  NMDA  receptor  antagonist  might  be 
useful as a neuroprotective drug in stroke and other 
neurodegenerative  disease  such  as  idiopathic  PD, 
where  it  has  been  suggested  that  brain-permeable 
L-type  calcium  channel  blockers  may  have  a  sa-
lutary  effect  on  the  disease. 
    NGP1-01  (8-benzylamino-8,11-oxapentacyclounde-
cane)  is  a  polycyclic  cage  amine  derived  from  the 
reductive  amination  of  benzylamine  and  Cookson's 
“bird  cage”  diketone  of  which  the  biology  was  first 
described  by  Van  der  Schyf  (Van  der  Schyf  et  al., 
1986)  (Fig.  10).  The  L-type  calcium  channel  block-Neuroprotective  and  Neurorestorative  Drugs 9
Fig.  10.  Chemical  structures  of  NGP-01  and  its  derivatives.
ing  activity  of  NGP1-01  was  investigated  utilizing 
electrophysiological  experiments  in  isolated  guinea- 
pig papillary muscle and sheep Purkinje fibers (Van 
der  Schyf  et  al.,  1986).  The  structural  similarity  of 
NGP1-01  to  another  polycyclic  cage  amine  and 
NMDA  receptor  antagonist,  memantine,  led  to  the 
evaluation of NGP1-01 for potential NMDA receptor 
antagonism.  Memantine  is  an  uncompetitive  NMDA 
receptor  antagonist  which  is  used  clinically  to  treat 
AD,  but  has  also  been  used  for  PD  in  Germany 
(Parsons  et  al.,  1999;  Rogawski  and  Wenk,  2003; 
Plosker and Lyseng-Williamson, 2005). Its favorable 
fast  on-off  binding  kinetics  gives  this  compound  an 
improved  side  effect  profile  compared  with  other 
NMDA antagonists such as MK-801 (Parsons et al., 
1999).  NGP1-01  was  shown  to  also  be  an  un-
competitive NMDA antagonist in murine whole brain 
synaptoneurosomes  and  blocked  NMDA-mediated 
45Ca
2＋ uptake with an IC50 of 2.98μM (Geldenhuys 
et  al.,  2007). 
    In  a  recent  paper  Kiewert  et  al.  (2006)  showed 
that  NGP1-01  (at  1μM)  inhibited  depolarization- 
induced  calcium  influx  by  78%  in  cortical  neurons 
preloaded with fura-2 AM, with a potency similar to 
that  of  nimodipine,  while  simultaneously  inhibiting 
NMDA-induced  (1  mM)  calcium  influx  by  52%,  only 
slightly  less  potent  than  memantine.  Using  in  vivo- 
microdialysis,  choline  release  was  monitored  during 
NMDA  infusion  as  a  measure  of  excitotoxic  mem-
brane breakdown. Intraperitoneal injection of NGP1- 
01  (40  mg/kg)  reduced  NMDA-induced  membrane 
breakdown  by  31%  (p＜0.01)  while  memantine  (10 
mg/kg)  reduced  choline  release  by  40%.  These 
results  demonstrate  that  NGP1-01  simultaneously 
blocks both major neuronal calcium channels and is 
brain-permeable after peripheral administration. This 
dual  mechanism  of  modulating  calcium  entry  into 
neuronal  cells  might  suggest  that  NGP1-01  may 
have utility as a neuroprotective agent in PD, stroke 
and other neurodegenerative diseases, especially in 
patients  with  comorbidity  among  these  diseases. 
This  promise  of  neuroprotection  has  recently  been 
partly  confirmed  in  in  vivo  studies  using  the  middle 
cerebral  artery  occlusion  (MCAO)  mouse  model  of 
stroke,  wherein  it  was  shown  that  NGP1-01,  ad-
ministered  30  minutes  before  MCAO,  afforded  sub-
stantial protection against cerebral ischemia-induced 
brain  lesioning,  as  well  as  brain  swelling  measured 
24  hours  after  MCAO  (Mdzinarishvili  et  al.,  2005). 
    Another  role  assigned  to  cage  amines  such  as 
NGP1-01  in  PD  therapy  is  the  ability  of  these 
compounds  to  inhibit  DA  re-uptake  into  nerve 
terminals  (Fig.  10).  Compounds  that  are  able  to 
block  the  DA  transporter  (DAT)  have  been  sug-
gested  to  be  more  useful  in  treating  the  motor 
symptoms in PD, as opposed to norepinephrine and 
serotonin re-uptake inhibitors (Hansard et al., 2002). 
Additionally,  compounds  with  the  ability  to  block 
DAT,  may  also  have  neuroprotective  activity  (Kirby 
et al., 2002). NGP1-01 was recently shown to block 
DA  re-uptake  in  murine  synaptosomes  with  an 
IC50 o f  5 7 μM.  One  of  NGP1-01’s  derivatives,  a 
phenylethylamine  derivative,  was  even  more  potent 
with  an  IC50 o f  2 3 μM  (Geldenhuys  et  al.,  2004). 
The  latter  compound  was  also  found  to  be  neu-
roprotective  in  the  MPTP-parkinsonian  mouse  mo-
del,  affording  protection  against  a  single  35  mg/kg 
(ip) dose of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyri-
dine  (MPTP)  (Geldenhuys  et  al.,  2003).
Green  tea  polyphenols
    Polyphenols  are  natural  products  present  in  be-
verages  such  as  red  wine  and  tea  (Weinreb  et  al., 
2004b).  One  of  the  classes  of  polyphenols  which 
are  pharmaceutically  interesting  is  the  flavenoids 
(Fig.  11).  These  compounds  are  characterized  by 
an  aromatic  ring  which  is  condensed  to  a  he-
terocyclic  ring  and  attached  to  a  second  aromatic 
ring.  An  innovative  therapeutic  approach  could  be 
the  use  of  natural  plant  polyphenol  flavonoids, 10 Moussa  B.  H.  Youdim
Fig.  11.  Chemical  structures  of  flavenoids  and  EGCG.
reported  to  have  access  to  the  brain  and  to 
possess  multifunctional  activities  as  iron  chelators, 
radical  scavengers,  anti-inflammatory  agents  and 
neuroprotectants  (Morel  et  al.,  1993;  Guo  et  al., 
1996;  Hider  et  al.,  2001;  Joseph  et  al.,  2005).
    These  compounds  and  their  actions  have  been 
extensively  reviewed  (Mandel  et  al.,  2005).  In  par-
ticular,  the  major  constituent  of  green  tea  catechin 
extract  (-)-epigallocatechin-3-gallate  (EGCG;  Fig.  11) 
plays  a  major  role  in  the  prevention  of  neuro-
degeneration  in  a  variety  of  cellular  and  animal 
models  of  neurodegenerative  diseases  (Mandel  et 
al.,  2006).  This  effect  appears  to  be  mediated 
through  multiple  pathways,  including  the  partici-
pation  of  the  pro-survival  PKC  and  extracellular 
mitogen-activated  protein  kinase  (MAPK)  signaling 
and  the  promotion  of  neurite  outgrowth  (Rezni-
chenko  et  al.,  2005).  Structurally  important  features 
defining  their  chelating  potential  are  the  3',4'- 
dihydroxyl  group  in  the  B  ring  (Hider  et  al.,  2001), 
as  well  as  the  gallate  group  (Kumamoto  et  al., 
2001)  which  may  neutralize  ferric  iron  to  form 
redox-inactive  iron,  thereby  protecting  cells  against 
oxidative  damage  (Grinberg  et  al.,  1997).  Recent 
studies have shown that prolonged administration of 
EGCG  to  mice  induced  a  significant  reduction  in 
membrane-associated  APP  levels  in  hippocampus 
(Levites  et  al.,  2003)  and  in  cerebral  Aβ levels 
concomitant  with  reduced  β-amyloid  plaques  (Re-
zai-Zadeh  et  al.,  2005).  This  effect  may  be  ac-
counted  for,  in  part,  by  the  chelation  of  the 
intracellular  free-iron  labile  pool,  modulating  APP 
mRNA  translation  via  its  IRE-type  II  (Reznichenko 
et  al.,  2006),  as  has  recently  been  described  for 
other  metal  chelators,  such  as  desferoxamine,  clio-
quinol and dimercaptopropanol (Payton et al., 2003; 
RogersLahiri,  2004).
DISCUSSION
    PD  and  AD  are  complex  diseases  with  multiple 
pathways which contribute to its etiology and finally 
cell  death  of  DA-ergic,  cholinergic  and  other  neu-
rons.  To  address  this  multiplicity,  compounds  that 
target  more  than  one  drug  target  in  the  cell  death 
cascades  are  now  investigated  and  designed.  The 
feasibility  of  moving  these  drugs  to  market  has 
been  shown  through  the  success  of  rasagiline, 
which  has  been  shown  to  have  neuroprotective 
activity  and  has  made  it  to  the  market  as  a  PD 
therapeutic (Olanow et al., 2009). The development 
of  multimodal  drugs  is  not  limited  to  neurode-
generative  disease,  but  rather  that  similar  ap-
proaches  are  under  way  with  other  complex  di-
sease  such  as  cancer,  AIDS,  depressive  illness, 
schizophrenia  and  possibly  cardiovascular  disorders 
(Youdim  and  Van  der  Schyf,  2009). 
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Executive  summary
Introduction
  ㆍPD,  AD  and  ALS  are  progressive  neurodegenerative  diseases
  ㆍMultiple  molecular  pathways  are  involved  in  the  cell  death  process
  ㆍSingle  targeted  ligands  may  not  modify  the  cell  death  process  since  the  other  pathways  may  still  be  contributing  to  cell  death
  ㆍMulti-functional  ligands  can  be  designed  to  target  more  than  one  drug  target  in  PD,  AD  and  ALS
Rasagiline
  ㆍRasagiline  is  a  second-generation  MAO-B  inhibitor
  ㆍIt  is  used  for  the  treatment  of  PD
  ㆍIt  has  also  been  shown  to  be  neuroprotective  and  neurorestorative
  ㆍIt  may  be  the  first  neuroprotective  disease  modifying  drug
Ladostigil-Monoamine  oxidase-cholinesterase
  ㆍLadostigil  multifunctional  drug  derivative  if  rasagiline  with  a  cholinesterase  inhibitor  moiety
  ㆍFor  use  in  AD  disease  with  parkinsonism,  Lewy  Body  disease  and  PD  with  dementia  and  depressive  illness
  ㆍIt  has  been  shghown  to  have  all  the  attributes  of  rasagiline  as  neuroprotective  and  neurorescue  drug
  ㆍIt  has  anti  depressant  activity  due  to  its  MAO-A  inhibitory  activity
M30  and  its  derivatives
  ㆍMultimodal  drug  iron  chelator-radical  scavenger  MAO-AB  inhibitor
  ㆍFor  use  in  PD,AD,  and  ALS
  ㆍNeuropriotective  and  neurorestorative
  ㆍNeurotrophic  activity,  BDNF,  VGEF,  erythropoietin
  ㆍInhibitor  of  Cyclin  D1resulting  in  cell  differentiation
Monoamine  oxidase/A2A  antagonists
  ㆍEpidemiology  has  suggested  caffeine  use  to  be  inversely  related t o  P D
  ㆍDual  MAO  and  A2A  antagonists  have  been  shown  to  be  neuroprotective 
NMDA/L-type  calcium  channel  blockers
  ㆍCalcium  overload  in  neuronal  cells  leads  to  cell  death
  ㆍTwo  major  routes  for  calcium  entry  into  cells  are  the  NMDA  receptor/ion  channel  as  well  as  the  L-type  calcium  channel
  ㆍNGP1-01  is a dual mechanism  drug which blocks both  the NMDA receptor/ion channel as well as  the L-type  calcium  channel,  with 
resulting  neuroprotective  activity  shown  in  vivo
  ㆍDAT  inhibition  by  NGP1-01  may  be  additionally  useful  in  treatment  of  the  motor  symptoms  of  PD
Green  tea  catechins
  ㆍGreen  tea  polyphenols  have  neuroprotective  properties
  ㆍMultiple  neuroprotective  mechanisms  are  suggested  including  anti-oxidant  and  metal  chelation
Future  perspective 
  ㆍMulti-functional  drugs  show  great  promise  as  neuroprotective-neurorescue  agents  in  neurodegenerative  diseases 
  ㆍMultiple drug targets can be targeted with a single compound, with less chance of side-effects such as associated with the practice 
of  polypharmacy
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